Welcome to our dedicated page for Acuren SEC filings (Ticker: TIC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Titan International鈥檚 filings dig deep into what drives the world鈥檚 tractors, combines and haul trucks鈥攐ff-the-road wheels, tires and undercarriage systems built for punishing fields and mines. That industry complexity shows up in equally dense disclosures about steel and rubber costs, farm-equipment cycles, and the Goodyear Farm Tires licensing agreement.
Finding those details inside a 300-page annual report or a mid-quarter 8-K is tough. Our AI-powered engine turns Titan International SEC filings into plain-English insights. Whether you need the Titan International insider trading Form 4 transactions alert, a quick read of the latest Titan International quarterly earnings report 10-Q filing, or context around a sudden plant shutdown revealed in an 8-K, the platform delivers real-time updates straight from EDGAR鈥攁lready summarized, tagged and searchable.
Here鈥檚 what you can uncover in seconds:
- 10-K & 10-Q 鈥� Segment revenue swings, commodity-price sensitivities, and foreign-exchange impacts, all presented in an Titan International annual report 10-K simplified format.
- Form 4 鈥� Titan International Form 4 insider transactions real-time to monitor when executives buy wheels for their own portfolios.
- Proxy Statement 鈥� Clarity on Titan International proxy statement executive compensation against cyclical performance targets.
- 8-K 鈥� Titan International 8-K material events explained so you know instantly when a plant re-tooling or royalty amendment hits the tape.
Use these AI-powered summaries to compare quarter-over-quarter margin trends, follow Titan International earnings report filing analysis, or simply save hours understanding Titan International SEC documents with AI. Complex filings become actionable insights鈥攏o heavy equipment required.
Acuren Corp (TIC) Form 4: Director James E. Lillie reported two equity transactions. On 30-Jul-2025, 10,000 restricted stock units (RSUs) vested and were settled for an equal number of common shares (Code M) at a stated price of $0, lifting his direct common-stock holding to 10,000 shares. On 31-Jul-2025, he received a new award of 9,017 RSUs (Code A) that will vest on 31-Jul-2026.
Lillie also has indirect exposure through Mariposa Acquisition IX, LLC, which owns 18,877,500 common shares and 1,000,000 Series A preferred shares (convertible 1-for-1). His estimated pecuniary interest in that vehicle equals 1,746,169 common shares plus 92,500 conversion-eligible shares, though he disclaims beneficial ownership beyond that economic stake. No shares were sold, and no cash changed hands; the preferred stock remains unconverted.
The filing signals continued equity alignment but is immaterial to Acuren鈥檚 share count and does not alter control dynamics.
Acuren Corp. (TIC) Form 4: Director Elizabeth Meloy Hepding reported routine equity-compensation activity.
- 07/30/2025 鈥� 10,000 previously granted restricted stock units (RSUs) vested and converted to an equal number of common shares (Code M) at a stated price of $0.
- 07/31/2025 鈥� Granted 9,017 new RSUs (Code A) that will vest on 07/31/2026.
After these transactions the insider directly owns 10,000 common shares and holds 9,017 unvested RSUs. No open-market buying or selling occurred, and cash consideration was zero, so the filing has no immediate impact on share count, liquidity, or earnings. It signals continued equity alignment between the director and shareholders but is not in itself a market-moving event.
Acuren Corp. (TIC) Form 4: Director Elizabeth Meloy Hepding reported routine equity-compensation activity.
- 07/30/2025 鈥� 10,000 previously granted restricted stock units (RSUs) vested and converted to an equal number of common shares (Code M) at a stated price of $0.
- 07/31/2025 鈥� Granted 9,017 new RSUs (Code A) that will vest on 07/31/2026.
After these transactions the insider directly owns 10,000 common shares and holds 9,017 unvested RSUs. No open-market buying or selling occurred, and cash consideration was zero, so the filing has no immediate impact on share count, liquidity, or earnings. It signals continued equity alignment between the director and shareholders but is not in itself a market-moving event.
Acuren Corp. (TIC) Form 4: Director Elizabeth Meloy Hepding reported routine equity-compensation activity.
- 07/30/2025 鈥� 10,000 previously granted restricted stock units (RSUs) vested and converted to an equal number of common shares (Code M) at a stated price of $0.
- 07/31/2025 鈥� Granted 9,017 new RSUs (Code A) that will vest on 07/31/2026.
After these transactions the insider directly owns 10,000 common shares and holds 9,017 unvested RSUs. No open-market buying or selling occurred, and cash consideration was zero, so the filing has no immediate impact on share count, liquidity, or earnings. It signals continued equity alignment between the director and shareholders but is not in itself a market-moving event.
Acuren Corp. (TIC) Form 4: Director Elizabeth Meloy Hepding reported routine equity-compensation activity.
- 07/30/2025 鈥� 10,000 previously granted restricted stock units (RSUs) vested and converted to an equal number of common shares (Code M) at a stated price of $0.
- 07/31/2025 鈥� Granted 9,017 new RSUs (Code A) that will vest on 07/31/2026.
After these transactions the insider directly owns 10,000 common shares and holds 9,017 unvested RSUs. No open-market buying or selling occurred, and cash consideration was zero, so the filing has no immediate impact on share count, liquidity, or earnings. It signals continued equity alignment between the director and shareholders but is not in itself a market-moving event.
Acuren Corp. (TIC) Form 4: Director Elizabeth Meloy Hepding reported routine equity-compensation activity.
- 07/30/2025 鈥� 10,000 previously granted restricted stock units (RSUs) vested and converted to an equal number of common shares (Code M) at a stated price of $0.
- 07/31/2025 鈥� Granted 9,017 new RSUs (Code A) that will vest on 07/31/2026.
After these transactions the insider directly owns 10,000 common shares and holds 9,017 unvested RSUs. No open-market buying or selling occurred, and cash consideration was zero, so the filing has no immediate impact on share count, liquidity, or earnings. It signals continued equity alignment between the director and shareholders but is not in itself a market-moving event.
Acuren Corp. (TIC) Form 4: Director Elizabeth Meloy Hepding reported routine equity-compensation activity.
- 07/30/2025 鈥� 10,000 previously granted restricted stock units (RSUs) vested and converted to an equal number of common shares (Code M) at a stated price of $0.
- 07/31/2025 鈥� Granted 9,017 new RSUs (Code A) that will vest on 07/31/2026.
After these transactions the insider directly owns 10,000 common shares and holds 9,017 unvested RSUs. No open-market buying or selling occurred, and cash consideration was zero, so the filing has no immediate impact on share count, liquidity, or earnings. It signals continued equity alignment between the director and shareholders but is not in itself a market-moving event.
On 1 July 2025, venture fund 5AM Opportunities I, L.P. filed a Form 144 indicating its intent to sell up to 6,422 common shares of Entrada Therapeutics, Inc. (NASDAQ: TRDA) through TD Securities (USA) LLC. The proposed transaction is valued at roughly USD 45,737 and represents only 0.02 % of Entrada鈥檚 37.95 million shares outstanding.
The filing also discloses that the same fund recently sold 19,265 shares on 27 Jun 2025 for USD 133,121 and 6,422 shares on 30 Jun 2025 for USD 43,751, bringing total sales in the past three months to 25,687 shares (鈮� 0.07 % of the float) for gross proceeds of approximately USD 176,872.
The shares were originally acquired on 29 Mar 2021 via a cash-financed venture investment. No operational, earnings, or strategic updates are provided in this notice. Form 144 merely gives advance notice of potential affiliate sales; execution is not assured. Given the small size relative to the public float, the filing is unlikely to materially affect liquidity or valuation but does indicate continued position trimming by an early investor.
FAQ
What is the current stock price of Acuren (TIC)?
What is the market cap of Acuren (TIC)?
What core services does Acuren Corp offer?
How does Acuren Corp support industrial markets?
What is nondestructive testing (NDT) and why is it important?
How does the Rope Access Technician Solutions (RAT) service work?
Why is lab testing a critical component of Acuren Corp's services?
How is Acuren Corp positioned within the competitive landscape?
What types of industries benefit from Acuren Corp's services?
What role does technical expertise play at Acuren Corp?
How does Acuren Corp maintain compliance and safety standards?
What distinguishes Acuren Corp in the realm of asset integrity services?
